“TB-500” is a product and research label, not a formal biochemical name. The “TB” is generally read as an abbreviation for Thymosin Beta.

The number 500 is a designation with no widely documented chemical meaning; it functions as a catalog or grade identifier rather than describing structure. Because the label is informal, materials sold under it are not guaranteed to share one exact sequence.

TB-500 is most often described as a short synthetic peptide corresponding to the actin-binding region of Thymosin Beta-4 (Tβ4), the full protein being 43 amino acids long.

The actin-binding motif of Tβ4 is commonly cited as LKKTETQ. Note an important caveat: some material sold as “TB-500” is reported to be full-length Tβ4 rather than this short fragment, so identity cannot be assumed from the name alone.

The parent molecule, Thymosin Beta-4, was identified through work on thymic peptide fractions by Allan Goldstein and colleagues in the 1960s and 1970s.

Tβ4 is found broadly in tissues and is one of the main proteins that binds and buffers actin monomers inside cells. TB-500 as a named research item emerged much later as a synthetic peptide keyed to that protein’s actin-binding function.

The design logic follows a common peptide-science strategy: take a large natural protein and reduce it to the shortest stretch that still reflects a specific functional region.

Because Tβ4 regulates actin, which is central to cell movement and structure, a short peptide tied to its actin-binding motif was of interest as a simpler research tool than the full 43-residue protein. Whether a short fragment reproduces the parent protein’s activities is a separate empirical question.

TB-500 is produced by solid-phase peptide synthesis (SPPS), the standard method for assembling short peptides one amino acid at a time on a resin support.

The crude product is purified by high-performance liquid chromatography (HPLC) and its identity confirmed by mass spectrometry. Because “TB-500” is not a standardized name, independent identity testing matters more here than for compounds with a single defined sequence.

Most published work concerns Thymosin Beta-4 itself, largely in cell and animal models, not the “TB-500” fragment as a distinct, well-characterized clinical entity.

Human clinical evidence for the fragment is limited, and efficacy for the uses it is informally associated with is not established. Sequence identity of commercial material is inconsistent. TB-500 is offered strictly for research use only (RUO); it is not an approved drug and is not for human or veterinary use.